Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.
Vranckx
Pascal
P
Cardialysis, Clinical Research Management & Core Laboratories, Rotterdam, The Netherlands.
Cutlip
Donald E
DE
Mehran
Roxana
R
Kint
Peter-Paul
PP
Silber
Sigmund
S
Windecker
Stephan
S
Serruys
Patrick W
PW
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000628:therapy*; D052279:Creatine Kinase, MB Form / Q000097:blood; D054855:Drug-Eluting Stents; D023381:Endpoint Determination; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D012008:Recurrence; D012680:Sensitivity and Specificity; D009626:Terminology as Topic; D016896:Treatment Outcome; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D014336:Troponin; D052279:Creatine Kinase, MB Form